Disproportionate improvement in obstructive sleep apnea relative to weight loss following tirzepatide therapy

Abstract

Obstructive sleep apnea (OSA) is a highly prevalent disorder with obesity which is its single most important modifiable factor. Tirzepatide, a dual agonist at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptorsthat has shown remarkable metabolic efficacy across manyrandomized trials. Whether its beneficial effects on sleep-disordered breathing work through mechanisms beyond total body weight reduction remains an active and clinically critical question. An equally important factor that is overlooked at times is considering the need to exclude thyroid dysfunction, particularly hypothyroidism as an independent and treatable driver of obesity and OSA. It must be ruled out before attributing clinical outcomes to pharmacotherapy.

We present a 46-year-old male journalist carrying a multimorbidity profile that included morbid obesity (initial weight 136 kg, BMI 44.1 kg/m²), poorly controlled type 2 diabetes mellitus (HbA1c 8.5%), hypertension, post-traumatic stress disorder, lumbar disc degeneration, and newly diagnosed severe OSA (Apnoea-Hypopnoea Index [AHI] 38.3 events/hour; nadir SpO₂ 57%). After Ruling out both hypothyroidism (a well-recognized cause of secondary obesity, pharyngeal myxedema, and blunted ventilatory drive) and hyperthyroidism (which can independently disrupt sleep and confound metabolic indices), tirzepatide was started at 2.5 mg weekly and titrated to 5.0 mg weekly. It was maintained over approximately 19 weeks and 4 days with complete adherence. The patient achieved a 14 kg weight reduction (10.4% total body weight loss). Yet hereported a clinically disproportionate improvement in OSA symptoms, near-resolution of habitual snoring without continuous positive airway pressure (CPAP) therapy. Adverse effects were self-resolving episodes of nausea and diarrhea.

This case supports the hypothesis that tirzepatide have beneficial effects on upper-airway physiology through multiple mechanisms that extend beyond the simple fat-mass reduction. Possibly includingselective reduction of pharyngeal adipose tissue, direct incretin-mediated anti-inflammatory actions, and neurohumoral modulation of airway collapsibility. The confirmed euthyroid state eliminates thyroid disease as a confounding variable and enhance the causal attribution of observed improvements to tirzepatide. Prospective studies incorporating objective polysomnographic reassessment are important to validate these mechanistic implications.